Home › Trial NCT05171335
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
- Trial IDNCT05171335
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorThe Methodist Hospital Research Institute
- Enrollment5
- Start date2022-08-20
- ConditionsHepatocellular Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.